Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Viasat (VSAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Viasat — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Viasat trades at $60.97 (market cap $9.21B). The key difference: Viasat is far larger — about 9.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is more actively traded (4,325,710 versus 1,494,317). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Viasat for 8 Days on average.
| MRVI | VSAT | |
|---|---|---|
Market Cap | $972.90M | $9.21B |
Volume | 4,325,710 | 1,494,317 |
Sector | Health | Technology |
52-Week High | $9.00 | $89.81 |
52-Week Low | $2.83 | $30.35 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $1.08B | $14.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
VSAT trades at $66.9, down 1.12% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $574.96 million in 2025, though revenue grew to $4.52 billion. Recent positive developments include the ViaSat-3 F2 and F3 satellites entering service and a $1 billion joint venture with Space42 to create Equatys for direct-to-device connectivity, signaling growth potential in government and commercial markets.
The outlook is mixed; analyst consensus is a Buy with a $94.29 price target, but near-term profitability challenges and high debt levels pose risks. The stock's investment case hinges on execution of new contracts and satellite deployments driving future earnings growth beyond current losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Viasat
Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →
